Anemia means the blood has reduced capacity to carry oxygen, and the consequences, from fatigue to organ dysfunction, all stem from that basic deficit. HBOT can dramatically increase the oxygen dissolved directly in plasma, bypassing hemoglobin entirely. This makes it theoretically attractive for anemia, and in specific life-threatening situations it is used exactly this way. But for chronic anemia, the picture is far more nuanced. Here’s what you need to know. It is one of several chronic conditions studied alongside HBOT that researchers are actively investigating.
How HBOT Relates to Anemia
Normal oxygen delivery relies on hemoglobin in red blood cells. Each hemoglobin molecule carries up to four oxygen molecules, and with normal hemoglobin levels and normal oxygen saturation, the blood carries approximately 20 mL of oxygen per 100 mL of blood. A very small additional amount (approximately 0.3 mL per 100 mL) is dissolved directly in plasma under normal atmospheric conditions.
When hemoglobin is severely reduced (acute anemia), oxygen-carrying capacity plummets. At 2.0 to 3.0 ATA of HBOT breathing 100% oxygen, plasma-dissolved oxygen increases dramatically, from 0.3 mL to roughly 6 mL per 100 mL of blood. In situations of profound anemia, this plasma-dissolved oxygen alone can sustain organ function. This is the scientific basis for emergency HBOT in anemia.1
Emergency HBOT for Life-Threatening Anemia
This is one of HBOT’s most dramatic and genuinely FDA-cleared applications. When a patient refuses blood transfusion (often for religious reasons, such as Jehovah’s Witnesses) or when compatible blood is not available, and hemoglobin has fallen to life-threatening levels, HBOT can serve as a bridge to allow the body’s natural erythropoiesis (red blood cell production) to recover or until a compatible donor can be found.
Published case reports and series document patients with hemoglobin levels as low as 2 to 3 g/dL (normal is 12 to 17 g/dL) surviving with HBOT support.2,3 These are extraordinary clinical situations where HBOT functions as a temporary life support measure rather than a treatment for the underlying anemia.
Sickle Cell Disease
Sickle cell disease is a hereditary hemoglobin disorder in which red blood cells adopt a rigid, sickle shape under low-oxygen conditions, blocking small blood vessels and causing painful vaso-occlusive crises, organ damage, and other complications. HBOT’s relationship with sickle cell is complex.
During an acute vaso-occlusive crisis, HBOT has been used to improve oxygenation and reduce sickling in the crisis area. Some case reports describe clinical improvement in acute chest syndrome (a life-threatening sickle cell complication) with HBOT. However, HBOT is not standard therapy for sickle cell disease, and there is concern that the hyperoxic environment could paradoxically worsen some aspects of the condition through reactive oxygen species generation in tissues with reperfusion injury. Sickle cell patients considering HBOT should consult their hematologist carefully before proceeding.
Chronic Anemia and HBOT
For the most common forms of chronic anemia, including iron deficiency anemia, vitamin B12 or folate deficiency anemia, anemia of chronic disease, and anemia related to kidney disease, HBOT has no established therapeutic role. These conditions are treated by addressing their root causes: iron supplementation, dietary correction, erythropoiesis-stimulating agents, or treating the underlying chronic disease.
HBOT does not stimulate red blood cell production in a clinically meaningful way for chronic anemia management. While some studies suggest HBOT may have modest effects on erythropoiesis through hypoxia-inducible factor (HIF) pathways, this effect is insufficient to make it a practical treatment for chronic anemia, and it would not address the underlying deficiency or disease causing the anemia.
Anemia in the Context of Other HBOT Indications
Many patients who receive HBOT for other approved indications (wound healing, radiation injury, osteomyelitis) also have concurrent anemia, often related to chronic disease, malnutrition, or the condition being treated. In these patients, anemia reduces the oxygen-carrying capacity that HBOT is trying to augment. Optimizing hemoglobin levels before and during HBOT may improve the therapy’s efficacy. This is a practical clinical consideration, not evidence that HBOT treats the anemia itself.
If you’re pursuing HBOT for wound healing or another condition and have concurrent anemia, it’s worth discussing this with your hyperbaric physician. Iron or B12 supplementation, or treatment of the underlying cause, alongside HBOT may optimize outcomes.
What Actually Helps Chronic Anemia
Rather than HBOT, the most effective interventions for chronic anemia depend entirely on the type. Iron deficiency anemia responds to iron supplementation (oral or IV). B12 deficiency responds to supplementation or injections. Anemia of chronic disease is best managed by treating the underlying condition. Anemia of chronic kidney disease often responds to erythropoiesis-stimulating agents and iron. Hemolytic anemias require condition-specific treatment. None of these require HBOT as an adjunct in the outpatient management setting.
The alternatives to HBOT article may be useful for comparing options when HBOT is not clearly indicated for your situation.
Treating Anemia Before Pursuing HBOT for Other Conditions
An important practical point: if you have concurrent anemia and are pursuing HBOT for another condition (wound healing, radiation injury, TBI), optimizing your hemoglobin levels before and during HBOT may meaningfully improve outcomes. HBOT works by increasing plasma-dissolved oxygen, but in severe anemia, the total oxygen delivery capacity remains limited even with HBOT. Getting hemoglobin to at least 10 to 11 g/dL before starting HBOT for other conditions is a reasonable target that may improve treatment response.
This is particularly relevant for cancer patients undergoing HBOT for radiation injury who may have treatment-related anemia, and for patients with chronic inflammatory conditions whose anemia of chronic disease has not been fully addressed. Discussing hemoglobin optimization with your physician before starting HBOT is a practical step that is often overlooked.
Nutritional Anemias and Recovery
Iron deficiency, B12 deficiency, and folate deficiency are among the most common and correctable causes of anemia. Correcting these deficiencies before pursuing HBOT for any condition improves overall physiological capacity for the therapy to work. Iron is a cofactor in the production of hemoglobin and also in collagen synthesis and oxidative killing by immune cells, two processes central to HBOT’s therapeutic mechanisms. A patient who is iron-deficient may have a blunted response to HBOT’s wound healing effects even if the HBOT itself is properly administered.
When Anemia Is the Result of the Condition Being Treated
Some conditions for which HBOT is used (radiation injury with chronic bleeding, severe wound infections with systemic inflammatory response) cause anemia as a consequence. In radiation cystitis with heavy hematuria, for example, significant bleeding anemia is common. In these cases, addressing the bleeding (which HBOT helps with) and supporting hemoglobin recovery (through iron supplementation, erythropoiesis-stimulating agents if appropriate, and occasionally transfusion) need to happen in parallel. The HBOT is treating the cause; the anemia management is supporting the patient’s capacity to respond.
Sickle Cell Crisis and Emergency HBOT
In acute sickle cell crises, particularly acute chest syndrome (which involves lung involvement, low oxygen saturation, and is the leading cause of death in sickle cell disease), HBOT has been used as a rescue intervention at some centers with mixed reported outcomes. Current sickle cell management guidelines do not include HBOT as a standard recommendation. If it is considered in an acute chest syndrome scenario, it would be as a last resort in a setting with appropriate monitoring and expertise, not as a standard intervention. Hematologists managing sickle cell disease should be central to any such decision.
Anemia and Recovery from HBOT Treatment
An often-overlooked issue is whether HBOT itself can cause anemia. In very long courses of HBOT (60+ sessions), some patients show mild reductions in red blood cell counts, possibly related to oxidative effects of high-pressure oxygen on red cell membranes. This is usually mild and clinically insignificant in most patients, but it’s worth monitoring hemoglobin periodically during extended courses of treatment, particularly in patients who are already borderline anemic. Adequate iron, B12, and folate status before and during HBOT is a reasonable precaution in longer courses.
Frequently Asked Questions
Can HBOT raise my hemoglobin level?
HBOT does not meaningfully raise hemoglobin levels in the way that treating the cause of anemia does. It increases plasma-dissolved oxygen (bypassing hemoglobin), but this is not the same as increasing red blood cell count or hemoglobin concentration. HBOT does not treat anemia; it compensates for it acutely in emergency situations.
I have anemia and fatigue. Would HBOT help my energy levels?
If your fatigue is driven by anemia, addressing the anemia directly (treating its cause) will be more effective than HBOT. HBOT is not evidence-based for anemia-related fatigue. If your fatigue persists after correcting anemia and you’re investigating other causes, HBOT for certain conditions (like post-COVID) might be relevant, but that’s a different clinical question.
Is HBOT used during cancer chemotherapy when anemia is a side effect?
HBOT is sometimes used in cancer patients for other indications (radiation injury, wound healing), and these patients often have treatment-related anemia. But HBOT is not used specifically to treat chemotherapy-induced anemia. Anemia in cancer patients is typically managed with erythropoiesis-stimulating agents, iron supplementation, or transfusion as needed. Several chemotherapy agents also have interactions with HBOT (notably bleomycin and doxorubicin), so any HBOT in cancer patients requires careful oncology coordination.
Sources
- Van Meter K. A systematic review of the application of hyperbaric oxygen in the treatment of severe anemia. Undersea Hyperb Med. 2005. PMID: 15796315
- Graffeo C, Dishong W. Severe blood loss anemia in a Jehovah’s Witness treated with adjunctive hyperbaric oxygen therapy. Am J Emerg Med. 2013. DOI: 10.1016/j.ajem.2012.11.013
- Johnson-Arbor K, Verstraete R. Use of hyperbaric oxygenation as an adjunctive treatment for severe pernicious anaemia in a bloodless medicine patient. BMJ Case Rep. 2021. DOI: 10.1136/bcr-2020-240619
- StatPearls. Hyperbaric Therapy in Blood Loss Anemia. NCBI NBK459379. NCBI
Medical Disclaimer
The content on BaricBoost.com is for informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
Author
Seph Fontane Pennock is the founder of BaricBoost.com and Regenerated.com, a clinic directory for regenerative medicine serving 10,000+ providers across the United States. He previously built and sold PositivePsychology.com, which grew to 19 million users and became the largest evidence-based positive psychology resource on the web. Seph brings direct experience as an HBOT patient, having completed protocols at clinics across three continents while navigating mold illness, systemic inflammation, and autoimmune conditions. His treatment journey includes hyperbaric oxygen therapy, peptide protocols, NAD+ therapy, and consultations with specialists from Dubai to Cape Town to Mexico. This combination of entrepreneurial track record and lived patient experience shapes everything published on BaricBoost.com. Every article is grounded in peer-reviewed research, informed by real clinical encounters, and written for patients making high-stakes treatment decisions. Seph's focus is on bringing transparency, scientific rigor, and practical guidance to the hyperbaric oxygen therapy space.
